Literature DB >> 1328798

Reversible or irreversible modification of [3H]PAF binding on rabbit platelet membranes differentiates various PAF receptor antagonists.

M T Domingo1, F Piro, C Broquet, E Auclair, P E Chabrier, P Braquet.   

Abstract

[3H]Platelet-activating factor (PAF) binding to rabbit platelet membranes was examined before and after 20 min preincubation at 25 degrees C in the presence of PAF, lysoPAF, or of five different PAF receptor antagonists (L 652731, BN 52021, WEB 2086, BN 52111 and BN 52115). When platelet membranes were not washed after preincubation with PAF or PAF antagonists, no significant specific binding of [3H]PAF was observed, which suggests full occupancy of the binding sites. When membranes were extensively washed, full recovery of specific [3H]PAF binding was attained with L 652731 and partial recoveries (60%, 55% and 30%) were reached with BN 52021, WEB 2086 and PAF, respectively; no recovery was seen with the dioxolanes BN 52111 and BN 52115. Scatchard analysis of the binding data indicated that no significant change in the dissociation constant (Kd) and maximum number of binding sites (Bmax) occurred after preincubation of platelet membrane with L 652731, whereas a reduction of Bmax was observed when PAF and BN 52021 were measured. When platelet membranes were preincubated with WEB 2086, Bmax and Kd significantly increased. The data suggest differing binding properties for PAF and the PAF antagonists. Some of the PAF antagonists may tightly bind to the PAF receptor site(s) and/or irreversibly modify or downregulate PAF recognition sites. Our results also suggest that the interaction of PAF receptor antagonists with PAF receptor can be divided into at least two components, namely a reversible component and an irreversible one.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1328798     DOI: 10.1007/bf02536114

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  22 in total

1.  Characterization of a platelet-activating factor receptor antagonist isolated from haifenteng (Piper futokadsura): specific inhibition of in vitro and in vivo platelet-activating factor-induced effects.

Authors:  T Y Shen; S B Hwang; M N Chang; T W Doebber; M H Lam; M S Wu; X Wang; G Q Han; R Z Li
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205

2.  Characterization of specific binding sites for PAF in the iris and ciliary body of rabbit.

Authors:  M T Domingo; P E Chabrier; J L Van Delft; N L Verbeij; N J Van Haeringen; P Braquet
Journal:  Biochem Biophys Res Commun       Date:  1989-04-14       Impact factor: 3.575

3.  The effects of PAF-acether on the cardiovascular system and their inhibition by a new highly specific PAF-acether receptor antagonist BN 52021.

Authors:  J Baranes; A Hellegouarch; M Le Hegarat; I Viossat; M Auguet; P E Chabrier; P Braquet
Journal:  Pharmacol Res Commun       Date:  1986-08

4.  Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators).

Authors:  C A Demopoulos; R N Pinckard; D J Hanahan
Journal:  J Biol Chem       Date:  1979-10-10       Impact factor: 5.157

5.  Pharmacological actions of WEB 2086, a new specific antagonist of platelet activating factor.

Authors:  J Casals-Stenzel; G Muacevic; K H Weber
Journal:  J Pharmacol Exp Ther       Date:  1987-06       Impact factor: 4.030

6.  BN 52021 displaces [3H]paf-acether from, and inhibits its binding to intact human platelets.

Authors:  R Korth; J Benveniste
Journal:  Eur J Pharmacol       Date:  1987-10-27       Impact factor: 4.432

7.  The actions of Paf-acether (platelet-activating factor) on guinea-pig isolated heart preparations.

Authors:  J Benveniste; C Boullet; C Brink; C Labat
Journal:  Br J Pharmacol       Date:  1983-09       Impact factor: 8.739

8.  Inhibitory effect of platelet-activating factor (PAF) on luteinizing hormone-releasing hormone and somatostatin release from rat median eminence in vitro correlated with the characterization of specific PAF receptor sites in rat hypothalamus.

Authors:  M P Junier; C Tiberghien; C Rougeot; V Fafeur; F Dray
Journal:  Endocrinology       Date:  1988-07       Impact factor: 4.736

9.  trans-2,5-Bis-(3,4,5-trimethoxyphenyl)tetrahydrofuran. An orally active specific and competitive receptor antagonist of platelet activating factor.

Authors:  S B Hwang; M H Lam; T Biftu; T R Beattie; T Y Shen
Journal:  J Biol Chem       Date:  1985-12-15       Impact factor: 5.157

10.  Specific receptor sites for 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine (platelet activating factor) on rabbit platelet and guinea pig smooth muscle membranes.

Authors:  S B Hwang; C S Lee; M J Cheah; T Y Shen
Journal:  Biochemistry       Date:  1983-09-27       Impact factor: 3.162

View more
  2 in total

Review 1.  Platelet-activating factor antagonists.

Authors:  M Koltai; P G Braquet
Journal:  Clin Rev Allergy       Date:  1994

2.  Capsaicin sensitive nerves in the jejunum of Nippostrongylus brasiliensis-sensitized rats participate in a cardiovascular depressor reflex.

Authors:  R Mathison; J S Davison
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-12       Impact factor: 3.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.